C. Schwartzkopf

Most-cited papers

1. The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases

   S. Correia, R. Iyengar, Peter Germano, K. Tang +15 more

   2021Frontiers in Pharmacology34 citations Open access

   Semantic Scholar

   Save

2. A growth-differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons.

   William B Smith, D. Nguyen, Timothy Clough, J. Schofield +13 more

   2024Journal of Clinical Endocrinology and Metabolism27 citations Open access

   Semantic Scholar

   Save

3. The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system

   S. Correia, Guang Liu, Sarah M. Jacobson, S. Bernier +13 more

   2021Journal of Neuroinflammation25 citations Open access

   Semantic Scholar

   Save

4. SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet

   Virginia Reverte, F. Rodríguez, L. Oltra, J. Moreno +6 more

   2022American Journal of Physiology. Heart and Circulatory Physiology15 citations Open access

   Semantic Scholar

   Save

5. A quantitative assay for the non-covalent association between apolipoprotein[a] and apolipoprotein B: an alternative measure of Lp[a] assembly.

   Beatriz N. Dardik, C. Schwartzkopf, D. E. Stevens, R. Chatelain

   2000Journal of Lipid Research8 citations

   Semantic Scholar

   Save

6. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity

   L. Jacobson, S. Commerford, Sarah P. Gerber, Y. Chen +12 more

   2011Naunyn-Schmiedeberg's Archives of Pharmacology7 citations

   Semantic Scholar

   Save

7. Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model

   C. Schwartzkopf, J. Hadcock, Guang Liu, Peter Germano +4 more

   2022Frontiers in Pharmacology5 citations Open access

   Semantic Scholar

   Save

8. Praliciguat, a Clinical-Stage sGC Stimulator, Improved Glucose Tolerance and Insulin Sensitivity and Lowered Triglycerides in a Mouse Diet-Induced Obesity Model

   C. Schwartzkopf, J. Hadcock, Juli E. Jones, M. Currie +2 more

   2018Diabetes4 citations

   Semantic Scholar

   Save

9. 1924-P: Praliciguat, a Clinical-Stage sGC Stimulator, Improves Insulin Sensitivity, Lipid Tolerance, and Energy Utilization in a Mouse Diet-Induced Obesity Model Housed at Thermoneutrality

   C. Schwartzkopf, J. Hadcock, Julien Roux, Guang Liu +5 more

   2019Diabetes1 citations

   Semantic Scholar

   Save

10. SUN-662 Praliciguat, a Clinical-Stage Soluble Guanylate Cyclase Stimulator, Improves Lipid Handling and Insulin Sensitivity in Diet-Induced Obese Mice

    C. Schwartzkopf, Guang Liu, J. Hadcock, M. Currie +2 more

    2020Journal of the Endocrine Society0 citations Open access

    Semantic Scholar

    Save

11. 1081-P: Metabolic Effects of Praliciguat, Empagliflozin, and Their Combination in Rats with Programmed Hypertension and Early Exposure to High-Fat Diet

    C. Schwartzkopf, V. R. Ribó, F. Rodríguez, L. Oltra +9 more

    20200 citations

    Semantic Scholar

    Save

12. 124-LB: Praliciguat, a Clinical-Stage Soluble Guanylate Cyclase (sGC) Stimulator, Improved Oral Glucose and Lipid Handling and Slowed Diabetic Weight Loss in TALLYHO Mice

    C. Schwartzkopf, Andrew Carvalho, J. Hadcock, M. Currie +1 more

    2020Diabetes0 citations

    Semantic Scholar

    Save